Here are four highlights:
1. In 2012 the market was worth $3.75 billion, and it grew at a 5.9 percent compound annual growth rate since.
2. North America and Europe dominate the market due to the high instances of arthritis and high obesity rates, creating a demand for bone grafting.
3. The Asia-Pacific region is expected to see the highest growth in 2019 due to the increase in orthopedic diseases caused by lifestyle changes and bone disorders.
4. Key market competitors include Medtronic, DePuy Synthes, Wright Medical, Stryker, Orthofix and NuVasive.
More articles on biologics:
DiscGenics reveals positive preclinical results for regenerative spine therapy — 5 takeaways
Spinal biologics — Will evidence support it? Key thoughts from Drs. D. Greg Anderson, Scott Blumenthal & William Tally
Aziyo Biologics launches OsteGro for spinal fusion, other procedures: 4 insights
